1Department of Endocrinology, The Second Hospital of Jilin University, Changchun, China
2Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China
3Department of Endocrinology, Children's Hospital of Nanjing Medical University, Nanjing, China
4Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University School of Medicine, Portland, OR, USA
5Section of Rheumatology, VA Portland Health Care System, Portland, OR, USA
Copyright © 2020 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conception or design: Y.L., C.Q.C., Y.L.
Acquisition, analysis, or interpretation of data: Y.L., Y.Z., M.Z., J.Z., Y.Z., X.Y.
Drafting the work or revising: Y.L., Q.L., H.C., C.Q.C., Y.L.
Final approval of the manuscript: Y.L., Y.Z., M.Z., J.Z., Y.Z., X.Y., Q.L., H.C., C.Q.C., Y.L.
Characteristic |
Microarray screening |
qRT-PCR validation |
||
---|---|---|---|---|
Control (n=3) | T1DM (n=3) | Control (n=12) | T1DM (n=12) | |
Age, yr | 16 (12–18) | 15 (12–17) | 12.6 (6–18) | 12.8 (5–17) |
Gender, female/male | 0/3 | 2/1 | 6/6 | 7/5 |
Disease duration, mo | - | 3.7±2.1 | - | 3.0±1.9 |
HbA1c, % | 5.6±0.1 | 9.7±0.8 | 5.4±0.4 | 9.9±1.2 |
Subjects positive for ≥1 islet Aba | 0 | 3 | 0 | 12 |
Serum C-peptide during OGTT, ng/mLb | ||||
0 min | - | 0.16±0.15 | - | 0.19±0.18 |
60 min | - | 0.21±0.18 | - | 0.39±0.37 |
120 min | - | 0.3±0.41 | - | 0.54±0.38 |
Values are presented as median (range) or mean±standard deviation.
qRT-PCR, quantitative real-time polymerase chain reaction; T1DM, type 1 diabetes mellitus; HbA1c, glycosylated hemoglobin; Ab, autoantibody; OGTT, oral glucose tolerance test.
a Number of subjects who were positive for at least 1 of the following islet autoantibodies: glutamic acid decarboxylase autoantibodies (GADA), insulinoma associated-2 autoantibodies (IA-2A), and zinc transporter-8 autoantibodies (ZnT8A),
b Serum C-peptide were measured 0 (fasting level), 60 and 120 minutes during OGTT.
Characteristic | Microarray screening |
qRT-PCR validation |
||
---|---|---|---|---|
Control (n=3) | T1DM (n=3) | Control (n=12) | T1DM (n=12) | |
Age, yr | 16 (12–18) | 15 (12–17) | 12.6 (6–18) | 12.8 (5–17) |
Gender, female/male | 0/3 | 2/1 | 6/6 | 7/5 |
Disease duration, mo | - | 3.7±2.1 | - | 3.0±1.9 |
HbA1c, % | 5.6±0.1 | 9.7±0.8 | 5.4±0.4 | 9.9±1.2 |
Subjects positive for ≥1 islet Ab |
0 | 3 | 0 | 12 |
Serum C-peptide during OGTT, ng/mL |
||||
0 min | - | 0.16±0.15 | - | 0.19±0.18 |
60 min | - | 0.21±0.18 | - | 0.39±0.37 |
120 min | - | 0.3±0.41 | - | 0.54±0.38 |
Values are presented as median (range) or mean±standard deviation. qRT-PCR, quantitative real-time polymerase chain reaction; T1DM, type 1 diabetes mellitus; HbA1c, glycosylated hemoglobin; Ab, autoantibody; OGTT, oral glucose tolerance test. Number of subjects who were positive for at least 1 of the following islet autoantibodies: glutamic acid decarboxylase autoantibodies (GADA), insulinoma associated-2 autoantibodies (IA-2A), and zinc transporter-8 autoantibodies (ZnT8A), Serum C-peptide were measured 0 (fasting level), 60 and 120 minutes during OGTT.